^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Krazati (adagrasib) (KRAS G12C inhibitor) + ENV-201 (ULK1 inhibitor, ULK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib
Published date:
10/12/2022
Excerpt:
We have demonstrated the added benefit of KRAS inhibition and autophagy inhibition in an animal model, using the NCI-H2122 cell line (homozygous for the activating KRASG12C mutation) as flank xenografts in NOD/SCID mice….Both ENV-201 and adagrasib treatments resulted in significant tumor growth inhibition when either drug was used as a single agent (32% or 55% TGI, respectively). Significant additive tumor growth inhibition (78%) was also observed when animals were treated with both drugs in combination.
